A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer
Date
2001
Authors
Olver, I.
Davy, M.
Luftner, D.
Park, S.
Egorin, M.
Ellis, A.
Webster, L.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Cancer Chemotherapy and Pharmacology, 2001; 48(2):109-114
Statement of Responsibility
Ian Olver, Margaret Davy, Diana Lüftner, So-Hyang Park, Merrill Egorin, Andrew Ellis, Lorraine Webster
Conference Name
Abstract
Purpose: The efficacy and pharmacokinetics of paclitaxel when combined with altretamine for ovarian cancer were studied. Methods: A group of 30 patients, whose only chemotherapy was one or more cisplatin-based non-paclitaxel-containing regimens and whose ovarian cancer failed to respond or had relapsed within 6 months of their last platinum regimen, received paclitaxel as a 3-h intravenous infusion and altretamine given orally in four divided doses daily for 14 days repeated every 28 days. Doses were escalated from paclitaxel/altretamine 135/150 mg/m2 to 250/300 mg/m2 in cohorts of three patients. Results: The dose-limiting toxicities at 250/300 mg/m2 were WHO grade 3 myalgias and arthralgias in two patients and grade 3 lethargy, stomach cramps, peripheral neuropathy and vomiting in single patients. Considering all dose levels in cycle 1, 16 patients had grade 3 or 4 neutropenia but there was only one episode of febrile neutropenia. Other grade 3 toxicities were vomiting in four patients, myalgias in three, peripheral neuropathy in two and lethargy in two. Grade 3 alopecia occurred in 23 patients. Three patients achieved a complete response and 12 achieved a partial response for an overall objective response rate of 50%. Responses occurred at all dose levels of 175/150 mg/m2 and higher. The median freedom from progression was 35 weeks, with a median survival of 55 weeks. Altretamine did not alter the pharmacokinetics of paclitaxel and there were no consistent differences in paclitaxel pharmacokinetic parameters or toxicities between course 1 and 2. No dose-response relationships were evident above paclitaxel/altretamine 175/150 mg/m2. Conclusion: Paclitaxel and altretamine can be safely combined and with a high response rate in relapsed ovarian cancer, justifying further studies with this combination.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© Springer, Part of Springer Science+Business Media